Literature DB >> 22588604

Compartment-specific gene regulation of the CAR inducer efavirenz in vivo.

H E Meyer zu Schwabedissen1, S Oswald, C Bresser, A Nassif, C Modess, Z Desta, E T Ogburn, M Marinova, D Lütjohann, C Spielhagen, M Nauck, H K Kroemer, W Siegmund.   

Abstract

Nuclear receptors such as the constitutive androstane receptor (CAR) are central factors that link drug exposure to the activities of drug metabolism and elimination. In order to determine the in vivo effects of efavirenz, a CAR activator, the expression of target genes was determined in duodenal biopsies obtained from 12 healthy volunteers before treatment and after 10 days of treatment with efavirenz; concomitant administration of the cholesterol inhibitor ezetimibe produced no significant difference. However, in in vitro studies, efavirenz significantly increased CYP2B6 expression in several cell types, suggesting that the drug transactivates CAR. This hypothesis is supported by our findings that there is significant induction of CAR target genes in in vivo peripheral blood mononuclear cells (PBMCs) isolated from healthy volunteers treated with multiple doses of efavirenz. The impact of efavirenz on hepatic metabolism in vivo was confirmed by significant changes in plasma 4β-hydroxycholesterol and bilirubin levels and the area under the curve (AUC) of efavirenz. Induction of CYP2B6 mRNA expression correlated with the decrease in the AUC of efavirenz (r = 0.61; P = 0.036). Taken together, our results provide evidence that efavirenz exerts compartment-specific inductive capacity in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22588604      PMCID: PMC3667667          DOI: 10.1038/clpt.2012.34

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  49 in total

1.  Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients.

Authors:  E Ngaimisi; S Mugusi; O M Minzi; P Sasi; K-D Riedel; A Suda; N Ueda; M Janabi; F Mugusi; W E Haefeli; J Burhenne; E Aklillu
Journal:  Clin Pharmacol Ther       Date:  2010-09-29       Impact factor: 6.875

2.  St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.

Authors:  L B Moore; B Goodwin; S A Jones; G B Wisely; C J Serabjit-Singh; T M Willson; J L Collins; S A Kliewer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 3.  Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.

Authors:  P F Smith; R DiCenzo; G D Morse
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor.

Authors:  Kaoru Kobayashi; Yosuke Yamanaka; Norihiko Iwazaki; Ikumi Nakajo; Masakiyo Hosokawa; Masahiko Negishi; Kan Chiba
Journal:  Drug Metab Dispos       Date:  2005-03-31       Impact factor: 3.922

5.  Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

Authors:  Christoph Wyen; Heidy Hendra; Marco Siccardi; Martin Platten; Hans Jaeger; Thomas Harrer; Stefan Esser; Johannes R Bogner; Norbert H Brockmeyer; Bernhard Bieniek; Juergen Rockstroh; Christian Hoffmann; Albrecht Stoehr; Claudia Michalik; Verena Dlugay; Alexander Jetter; Heribert Knechten; Hartwig Klinker; Adriane Skaletz-Rorowski; Gerd Fätkenheuer; Deirdre Egan; David J Back; Andrew Owen
Journal:  J Antimicrob Chemother       Date:  2011-06-29       Impact factor: 5.790

6.  Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.

Authors:  John G Gerber; Susan L Rosenkranz; Carl J Fichtenbaum; Jose M Vega; Amy Yang; Beverly L Alston; Susan W Brobst; Yoninah Segal; Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2005-07-01       Impact factor: 3.731

Review 7.  CAR: detailing new models.

Authors:  Bryan Goodwin; John T Moore
Journal:  Trends Pharmacol Sci       Date:  2004-08       Impact factor: 14.819

8.  Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans.

Authors:  Thomas Giessmann; Karen May; Christiane Modess; Danilo Wegner; Ute Hecker; Michael Zschiesche; Peter Dazert; Markus Grube; Eike Schroeder; Rolf Warzok; Ingolf Cascorbi; Heyo K Kroemer; Werner Siegmund
Journal:  Clin Pharmacol Ther       Date:  2004-09       Impact factor: 6.875

Review 9.  Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.

Authors:  Francesca Borrelli; Angelo A Izzo
Journal:  AAPS J       Date:  2009-10-27       Impact factor: 4.009

10.  The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.

Authors:  Becky Chandler; Lisa Almond; Jennifer Ford; Andrew Owen; Patrick Hoggard; Saye Khoo; David Back
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-15       Impact factor: 3.731

View more
  11 in total

1.  Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.

Authors:  Doo-Yeoun Cho; Joan H Q Shen; Suzanne M Lemler; Todd C Skaar; Lang Li; Julia Blievernicht; Ulrich M Zanger; Kwon-Bok Kim; Jae-Gook Shin; David A Flockhart; Zeruesenay Desta
Journal:  Drug Metab Pharmacokinet       Date:  2015-07-29       Impact factor: 3.614

Review 2.  Small-molecule modulators of the constitutive androstane receptor.

Authors:  Milu T Cherian; Sergio C Chai; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-05-15       Impact factor: 4.481

3.  Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.

Authors:  Zeruesenay Desta; Ingrid F Metzger; Nancy Thong; Jessica B L Lu; John T Callaghan; Todd C Skaar; David A Flockhart; Raymond E Galinsky
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

4.  Response to "Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction".

Authors:  Prasanna Jagannathan; Richard Kajubi; Francesca T Aweeka
Journal:  Clin Pharmacol Ther       Date:  2018-01-11       Impact factor: 6.875

5.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Authors:  Zeruesenay Desta; Roseann S Gammal; Li Gong; Michelle Whirl-Carrillo; Aditya H Gaur; Chonlaphat Sukasem; Jennifer Hockings; Alan Myers; Marelize Swart; Rachel F Tyndale; Collen Masimirembwa; Otito F Iwuchukwu; Sanika Chirwa; Jeffrey Lennox; Andrea Gaedigk; Teri E Klein; David W Haas
Journal:  Clin Pharmacol Ther       Date:  2019-07-05       Impact factor: 6.875

6.  zzm321990 zzm321990 Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers.zzm321990 zzm321990

Authors:  Brandon T Gufford; Ingrid F Metzger; Nadia O Bamfo; Eric A Benson; Andrea R Masters; Jessica Bo Li Lu; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2022-07-07       Impact factor: 4.402

7.  Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers.

Authors:  Kimberly S Collins; Ingrid F Metzger; Brandon T Gufford; Jessica B Lu; Elizabeth B Medeiros; Victoria M Pratt; Todd C Skaar; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2019-12-30       Impact factor: 3.922

8.  Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.

Authors:  Ingrid F Metzger; Troy C Quigg; Noam Epstein; Abdulateef O Aregbe; Nancy Thong; John T Callaghan; David A Flockhart; Anne T Nguyen; Colleen K Stevens; Samir K Gupta; Zeruesenay Desta
Journal:  Curr Ther Res Clin Exp       Date:  2014-09-27

9.  CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers.

Authors:  Ingrid F Metzger; Nimita Dave; Yvonne Kreutz; Jessica B L Lu; Raymond E Galinsky; Zeruesenay Desta
Journal:  Clin Transl Sci       Date:  2019-08-12       Impact factor: 4.689

10.  MicroRNA Mediated Changes in Drug Metabolism and Target Gene Expression by Efavirenz and Rifampicin In Vitro: Clinical Implications.

Authors:  Marelize Swart; Collet Dandara
Journal:  OMICS       Date:  2019-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.